Investors-in-residence join Cancer Research Horizons to advance Ventures team

Jonathan Tobin, a partner at life science venture capital firm Brandon Capital, and Genghis Lloyd-Harris, a senior advisor at life sciences investment firm, Abingworth, have joined Cancer Research Horizons’ Ventures team as advisory investors-in-residence. Jonathan and Genghis will also join the Investment Committee for Cancer Research Horizons’ £30 million Seed Fund*, set up to support the formation of new companies that offer cutting-edge cancer-beating ideas and discoveries.

Cancer Research Horizons, Cancer Research UK’s innovation engine, has access to over £400 million of cutting-edge cancer research every year which it helps reach cancer patients by translating breakthroughs into new treatments, diagnostics and technologies.

But not enough of the promising new ideas and innovations cancer researchers make reach patients because there is a funding gap between academic research and taking drugs and treatments to the market. Cancer Research Horizons’ specialist Ventures team helps bridge that gap by investing its new Seed Fund in identifying and validating breakthrough opportunities and supporting new oncology companies to form and progress to being ready for further investment. This year alone the team has agreed to provide early-stage funding to eight new ventures.

Jonathan Tobin and Genghis Lloyd-Harris will bring a wealth of venture capital experience to the Ventures team, helping grow the number and quality of the companies the Seed Fund supports – from scouting for opportunities to scrutinising the selection process for funding and building networks of other experts to support new company development.

Tony Hickson, Chief Business Officer at Cancer Research Horizons, said, “The Ventures team is tackling the translational funding gap head-on to prevent breakthrough ideas stalling in their early phases. Our new investors-in-residence will have a huge impact by helping us find more opportunities, ensure their quality and advise on building scale and capabilities. They have deep understanding of what will make a new company likely to succeed, ultimately enabling treatments to reach patients.”

Jonathan is a partner with Brandon Capital where he heads the London office, and serves on the boards of Brandon portfolio companies Astronautx, Pheon Therapeutics, Myricx Bio, NRG Therapeutics, and Catalym. Prior to joining Brandon, Jonathan was a managing director at Arix Bioscience, a UK- and US-based biotech venture firm, where he helped build the team and portfolio, and sat on the boards of a number of companies. Prior to Arix, he was a principal of Imperial Innovations/Touchstone Innovations PLC and helped create and build several university spinouts.

Jonathan has a degree in biology from the University of Oxford and a PhD in molecular medicine from UCL focusing on rare genetic diseases. He carried out postdoctoral research on cancer cell signalling at the Cancer Research UK London Research Institute (now the Francis Crick Institute) before gaining an MBA with distinction from Imperial College London. He serves as a trustee on the board of the Autism Centre for Excellence in Cambridge and is a member of the Investment Advisory Committee of the KHAN drug discovery fund in Germany.

Genghis is a physician-scientist and investor with over 30 years of transatlantic industry experience in finance and venture capital, across biopharmaceuticals, clinical co-development, life science tools and medical devices.

Genghis is a managing partner at leading life sciences investment firm, Abingworth, where he identifies and invests in new businesses and supports portfolio companies. He focuses on exits of venture investments via mergers and acquisitions and IPOs. Genghis’ current and past board positions include Avillion, GenSight Biologics, Healthcare Brands International, Nouscom, Novexel, Solexa, Synosia, Syntaxin and Wilson Therapeutics.

Genghis joined Abingworth in 2004 from Credit Suisse First Boston where he was managing director in the European Equity Research Group based in London responsible for coverage of the European biotechnology industry.

Genghis was a paediatrician in Melbourne, Australia, and holds a medical degree from the University of Liverpool, a PhD in clinical pharmacology from the University of Melbourne and an MBA from Harvard Business School.

 

More news and updates 

UKHSA announced as first PACE collaboration to help tackle deadly antimicrobial resistance

Strategic partnership to support AMR innovators

PrecisionLife and Metrodora Institute partner to accelerate diagnosis of Long COVID

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases; targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year

Optibrium enables collaborative design in its StarDrop platform

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking.

BugBiome secures investment for pioneering research in sustainable pest protection

BugBiome raises £310,000 in pre-seed investment from Cambridge Angels and Discovery Park Ventures. Investment enables a £330,000 Engineering Biology Grant from Innovate UK for cutting-edge agri-tech research leveraging the microbiome and engineering biology approaches.

Study reveals POLB 001 could be a $10 billion game changer for cancer patients

Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS). Former Amryt Pharma team's arrival supports increasing focus upon Rare and Orphan Diseases

Demand for Golden Triangle lab space surges with highest annual volume since 2015

Demand for life sciences space in the ‘Golden Triangle’ surged in 2023, with the 925,000 sq ft of space representing the highest annual volume since 2015, according to the latest figures from Cushman & Wakefield.

New £100 million engineering biology fund

Six new Engineering Biology Mission Hubs and 22 Mission Awards, to transform solutions in areas like vaccine development, textile manufacturing and food production; New investments to unlock potential of engineering biology as part of the wider National Engineering Biology Programme

Pioneer Group’s regeneration plans for Cambridge’s Grafton Centre approved

Pioneer Group, a leading developer and operator of life science and high-tech campuses, has secured planning permission from Cambridge City Council, subject to S106, for the redevelopment of the Grafton Centre in the city.

Novel drug and software combo tackles hypertension with personalised treatment

Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalised dose optimisation, today announced the publication of a peer-reviewed study in the Journal of the American Heart Association (JAHA) (1).

NICE endorses Brainomix AI-enabled software in Stroke

New guidance from NICE, the globally respected health assessor, acknowledges the impact that Brainomix 360 has demonstrated on stroke care, expanding patient access to life-changing treatments

 

More within